| Category | BioTech |
| Phone | 401-333-3789 |
| Employees | |
| Founded | 1995 |
| TOTAL | $40M |
| FUNDING TOTAL | $40M |
| Venture Round, 9/06 TVM Capital Lurie Investment Fund MDS Capital Merlin Biomed TSC BioVenture Capital Corporation Apjohn ventures BD Ventures Bio*One Capital North Coast Technology Investors | $40M |
RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizes physiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island.
